From Wikipedia, the free encyclopedia
Jump to: navigation, search
Cycloguanil sf.png
Clinical data
ATC code
CAS Number
PubChem CID
Chemical and physical data
Formula C11H14ClN5
Molar mass 251.715 g/mol
3D model (JSmol)

Cycloguanil is a dihydrofolate reductase inhibitor,[1] and is a metabolite of the antimalarial drug proguanil; its formation in vivo has been thought to be primarily responsible for the antimalarial activity of proguanil.[2] However, more recent work has indicated that, while proguanil is synergistic with the drug atovaquone (as in the combination Malarone), cycloguanil is in fact antagonistic to the effects of atovaquone, suggesting that, unlike cycloguanil, proguanil may have an alternative mechanism of antimalarial action besides dihydrofolate reductase inhibition.[3]

Although cycloguanil is not currently in general use as an antimalarial, the continuing development of resistance to current antimalarial drugs has led to renewed interest in studying the use of cycloguanil in combination with other drugs.[4]


  1. ^ Srivastava IK, Vaidya AB; Vaidya (June 1999). "A mechanism for the synergistic antimalarial action of atovaquone and proguanil". Antimicrob. Agents Chemother. 43 (6): 1334–9. PMC 89274Freely accessible. PMID 10348748. 
  2. ^ Watkins, W. S.; Sixsmith, D. G.; Chulay, J. D. (Jun 1984). "The activity of proguanil and its metabolites, cycloguanil and p-chlorophenylbiguanide, against Plasmodium falciparum in vitro" (Free full text). Annals of Tropical Medicine and Parasitology. 78 (3): 273–278. ISSN 0003-4983. PMID 6385887. 
  3. ^ Thapar, M. G.; Gupta, S.; Spindler, C.; Wernsdorfer, W. H.; Björkman, A. (May 2003). "Pharmacodynamic interactions among atovaquone, proguanil and cycloguanil against Plasmodium falciparum in vitro". Transactions of the Royal Society of Tropical Medicine and Hygiene. 97 (3): 331–337. doi:10.1016/S0035-9203(03)90162-3. ISSN 0035-9203. PMID 15228254. 
  4. ^ Walzer, P. ; F.; Foy, J.; Steele, P.; White, M. (Jul 1993). "Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis". Antimicrobial Agents and Chemotherapy. 37 (7): 1436–1443. doi:10.1128/AAC.37.7.1436. ISSN 0066-4804. PMC 187990Freely accessible. PMID 8363372.